Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 6/20 | 0.42 |
| ▸ | UCHL1 | P09936 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SCN4A | P35499 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1250737 | 0.87 | HSD17B10 (0.49) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL1257155 | 0.87 | HSD17B10 (0.49) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL5328715 | 0.87 | HSD17B10 (0.49) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL31048243 | 0.86 | HSD17B10 (0.48) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL5427850 | 0.85 | HSD17B10 (0.52) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL5427853 | 0.85 | HSD17B10 (0.52) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL2492664 | 0.85 | HSD17B10 (0.52) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL25395953 | 0.83 | HSD17B10 (0.53) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL1584759 | 0.83 | HSD17B10 (0.53) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 | |
| SCHEMBL903492 | 0.83 | HSD17B10 (0.53) | HSD17B10SMN1; SMN2NPC1LMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080242709-A1 | 2-AMIDO-4-ISOXAZOLYL THIAZOLE COMPOUNDS EXHIBITING ATP-UTILIZING ENZYME INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | GENENTECH, INC. | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242709-A1 | 2-AMIDO-4-ISOXAZOLYL THIAZOLE COMPOUNDS EXHIBITING ATP-UTILIZING ENZYME INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | ATP5ME, ATP5MG, ATP5MK | HSD17B10 1252/4885SMN1; SMN2 4150/4885NPC1 2067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.